Development Milestone Events. [...***...]* [...***...] [...***...] [...***...] Reaching [...***...]* [...***...] [...***...] [...***...] [...***...]** [...***...] [...***...] [...***...] [...***...]** [...***...] [...***...] [...***...] [...***...]*** [...***...] [...***...] — [...***...] — — [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...] [...***...]
Development Milestone Events. [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Other Milestone Events: [**] [**] [**] [**] [**] [**] [**].
Development Milestone Events. Subject to the terms and conditions of this Agreement, if Licensee exercises the TARP8 Option pursuant to Section 2.2.3 (Option Exercise), Licensee will pay to Xxxxxxx each of the applicable milestone payments set forth in the table below upon the first (1st) achievement of the applicable development milestone event of a TARP8 Product. For clarity, each development milestone payment in this Section 6.3.1.1 (Development Milestone Events) will be payable only once and will be non-refundable and non-creditable. Development Milestone Event Development Milestone Payment (USD) Any [***] Lead Candidate Product 1 [***] $[***] 2 [***] $[***] 3 [***] $[***] 4 [***] $[***] 5 [***] $[***] 6 [***] $[***] Total $76,000,000 Any TARP8 Development Candidate Product other than a [***] Lead Candidate Product 7 [***] $[***] 8 [***] $[***] Total $25,000,000 Licensee will provide Xxxxxxx with written notice of the first achievement of each development milestone event for each TARP8 Product within [***]. Licensee will make the corresponding development milestone payments to Xxxxxxx within [***]. [***]
Development Milestone Events. The third milestone event in Table 1 for $[…***…] shall be amended and restated as follows: “[…***…]”
Development Milestone Events. (a) RX-0047 Product. Subject to the terms and conditions set forth in this Section 4.2, HaiChang shall make each of the one-time, non-refundable, non-creditable milestone payments to Rexahn that are set forth below upon the first occurrence of the corresponding milestone event by or on behalf of HaiChang or its Affiliates with respect to an RX-0047 Product. Each milestone payment under this Section 4.2(a) shall be paid only once with respect to the first time such milestone event is achieved.
Development Milestone Events. Subject to the remainder of this Section 9.2, on an Exclusive Gene Target-by-Exclusive Gene Target basis, Novartis shall pay to Sangamo the non-refundable, non-creditable payments set forth in the table below (each, a “Development Milestone Payment”) upon the first achievement of the applicable event listed below (each, a “Development Milestone Event”) by Novartis, any of its Affiliates or Sublicensees with respect to a ZFP, [*] or Product, as applicable, that Specifically Binds to such Exclusive Gene Target: [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Confidential Execution Version Development Milestone Event Development Milestone Payment [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*]
Development Milestone Events. Subject to the terms and conditions set forth in this Section 5.2(a), 3DMed shall make each of the one-time, non-refundable, non-creditable milestone payments to SELLAS that are set forth below upon the first occurrence of the corresponding development milestone event by or on behalf of 3DMed or its Sublicensee with respect to a Licensed Product. Each milestone payment under this Section 5.2(a) shall be paid only once with respect to the first time such development milestone event is achieved. In the event that a development milestone event is achieved and an earlier development milestone event has not been achieved (e.g., development milestone event 5 is achieved before development milestone event 4), then such earlier development milestone event shall be deemed to have been achieved at the same time as the later development milestone event and 3DMed shall pay to SELLAS the milestone payment for such earlier development milestone event at the same time that the milestone payment for the later development milestone event is paid.
Development Milestone Events. [***]* [***] [***] [***] Reaching [***]* [***] [***] [***] [***]** [***] [***] [***] [***]** [***] [***] [***] [***]*** [***] [***] — [***] — — [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Milestone Events: [***] [***] [***] [***] [***] [***] [***] [***] TOTAL Potential Milestones [***] [***] [***] *These milestones are payable upon achievement of the event, regardless of whether [***] or not. The [***] Milestone Event shall occur upon [***] that the Discovery Milestone has been met. **For each of these milestones, GSK pays the Table 1 Rate or Table 2 Rate, as applicable, if GSK achieves the Milestone Event (i.e., if GSK had exercised its Program Option at [***] Stage or otherwise prior to [***]) or the Table 3 Rate if Regulus achieves the Milestone Event (i.e., if GSK had not so exercised its Program Option but Regulus continued developing the Collaboration Compound). ***This milestone is only payable where GSK exercises the Program Option prior to [***]. This Milestone Event will be met as determined by GSK; provided, however, that the Milestone Event will be deemed to have been met if, after conducting a [***], GSK moves the relevant Program forward through clinical development by Initiating either a [***] with respect to such Program. In addition, if GSK has not [***] but has not terminated the Program and returned the Collaboration Compounds under such Program to Regulus as Returned Licensed Products, then this Milestone Event will be deemed to have been met.
Development Milestone Events. Subject to the terms and conditions set forth in Section 4.10(b) and this Section 5.2, Qilu shall make each of the one-time, non-refundable, non-creditable milestone payments to Sesen that are set forth below upon the first occurrence of the corresponding milestone event by or on behalf of Qilu or its Sublicensee with respect to the first Licensed Product. Each milestone payment under this Section 5.2 shall be paid only once with respect to the first time such milestone event is achieved.
Development Milestone Events. In further consideration of the licenses and rights granted to Novartis hereunder, upon [***] achievement by Novartis, its Affiliates, or its or their Sublicensees of a Development Milestone Event set forth below [***], the corresponding [***] Development Milestone Payment shall become payable by Novartis to Legend: Development Milestone Event Development Milestone Payment
